Last edition
News about "oveporexton Japan approval"
Japan Approves Takeda's ORZEYFUL (Oveporexton) for Narcolepsy Type 1
Japan approves ORZEYFUL (oveporexton) as the first and only medicine targeting the underlying cause of narcolepsy type 1, following positive phase 3 results.
Oveporexton Japan Approval | 24/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members